Citadel Advisors’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.72M | Buy |
|
|||||
|
2025
Q2 | $1.62M | Buy |
|
|||||
|
2025
Q1 | $1.72M | Buy |
|
|||||
|
2024
Q4 | $137K | Sell |
|
|||||
|
2024
Q3 | $419K | Sell |
|
|||||
|
2024
Q2 | $963K | Sell |
|
|||||
|
2024
Q1 | $1.15M | Sell |
|
|||||
|
2023
Q4 | $5.66M | Buy |
|
|||||
|
2023
Q3 | $23M | Buy |
|
|||||
|
2023
Q2 | $27.1M | Sell |
|
|||||
|
2023
Q1 | $25.1M | Buy |
|
|||||
|
2022
Q4 | $16.9M | Sell |
|
|||||
|
2022
Q3 | $17.6M | Buy |
|
|||||
|
2022
Q2 | $13.3M | Sell |
|
|||||
|
2022
Q1 | $16.8M | Sell |
|
|||||
|
2021
Q4 | $14.7M | Sell |
|
|||||
|
2021
Q3 | $19.1M | Sell |
|
|||||
|
2021
Q2 | $21.6M | Sell |
|
|||||
|
2021
Q1 | $33.4M | Buy |
|
|||||
|
2020
Q4 | $267K | Buy |
|
|||||
|
2020
Q3 | $65K | Buy |
|
|||||
|
2020
Q2 | – | Sell |
|
|||||
|
2020
Q1 | $53K | Buy |
|
|||||
|
2019
Q4 | $51K | Sell |
|
|||||
|
2019
Q3 | $80K | Buy |
|
|||||
|
2019
Q2 | $71K | Sell |
|
|||||
|
2019
Q1 | $1.13M | Sell |
|
|||||
|
2018
Q4 | $4.1M | Sell |
|
|||||
|
2018
Q3 | $12.8M | Buy |
|
|||||
|
2018
Q2 | $17.3M | Sell |
|
|||||
|
2018
Q1 | $15.7M | Buy |
|
|||||
|
2017
Q4 | $3.66M | Sell |
|
|||||
|
2017
Q3 | $6.25M | Buy |
|
|||||
|
2017
Q2 | $911K | Sell |
|
|||||
|
2017
Q1 | $1.52M | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $238K | Buy |
|